ResearcherSLK-Kliniken HeilbronnActive in the last 2 years
Stephanie Berger
Known by name at one institution; no external author ID yet. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 3
2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 2
- Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag108↗
- Sustainable Response of a Patient With Metastasized Pancreatic Cancer and a Hypermutational Phenotype to Immunotherapy. New Therapeutic Concept for a Rare Subt… Co-author DOI 10.1200/po.18.00005↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Uwe M. Martens · 2 shared papers, 2018–2026 · strength 0.36
- Paper Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreat… DOI 10.1093/oncolo/oyag108↗
- Paper Sustainable Response of a Patient With Metastasized Pancreatic Cancer and a Hypermutational Phenotype to Immunotherapy.… DOI 10.1200/po.18.00005↗
- Bence Sipos · 2 shared papers, 2018–2026 · strength 0.36
- Paper Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreat… DOI 10.1093/oncolo/oyag108↗
- Paper Sustainable Response of a Patient With Metastasized Pancreatic Cancer and a Hypermutational Phenotype to Immunotherapy.… DOI 10.1200/po.18.00005↗
- Sarah Rohlfing · 1 shared paper, 2026 · strength 0.29
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.